Miller Value Partners’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Miller Value Partners’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-164,998	Closed	-$30M	–	89
2023 Q1	$30M	Buy	164,998 +20,032	+14%	+$3.83M	1.87%	27
2022 Q4	$28.5M	Sell	144,966 -25,369	-15%	-$5.44M	1.84%	27
2022 Q3	$38.3M	Sell	170,335 -52,620	-24%	-$10.7M	2.33%	23
2022 Q2	$28.2M	Sell	222,955 -18,893	-8%	-$2.17M	1.43%	28
2022 Q1	$30.7M	Buy	241,848 +525	+0.2%	+$59.1K	0.99%	35
2021 Q4	$31.6M	Buy	241,323 +1,898	+0.8%	+$245K	0.87%	39
2021 Q3	$29.3M	Sell	239,425 -57,864	-19%	-$6.68M	0.68%	42
2021 Q2	$33.9M	Buy	297,289 +6,050	+2%	+$707K	0.81%	41
2021 Q1	$35M	Buy	+291,239	New	+$33M	0.91%	42

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Miller Value Partners's KRTX Position: Q2 2023 in Review

Miller Value Partners sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q2 2023, closing a stake of 164,998 shares — an estimated $30M sold.

Miller Value Partners first reported a position in KRTX in Q1 2021 and held it in 9 quarters. The position peaked at $38.3M in Q3 2022. 288 funds tracked by Wall St. Rank hold KRTX as of Q2 2023.

Miller Value Partners reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Miller Value Partners sold 164,998 Karuna Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $30M.
Miller Value Partners first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
Miller Value Partners's Karuna Therapeutics, Inc. Common Stock position peaked at $38.3M in Q3 2022.
288 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Miller Value Partners's 13F filing for Q2 2023, filed 14 Aug 2023.